Companies KALA BIO, Inc.
KALA BIO (KALA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me KALA BIO, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $8,342,714FY2023
- $1,491,187FY2024
- $906,642FY2025
CEO total pay was $906,642 in fiscal 2025, down from $1,491,187 in fiscal 2024.
FY2025: salary $111,866 · bonus $0 · stock awards $166,413 · option awards $627,467
Order KALA
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Todd Bazemore | $489,112 | $585,450 | $76,053 | $2,262,211 | $0 | $0 | $64,146 | $3,476,972 |
| Former Interim Chief Executive Officer, President and Chief Operating Officer | ||||||||
| Kim Brazzell | 420,000 | 522,000 | 76,053 | 285,040 | 0 | 0 | 55,081 | 1,358,174 |
| Former Head of Research and Development and Chief Medical Officer | ||||||||
| Mary Reumuth | 438,962 | 475,550 | 76,053 | 285,040 | 0 | 0 | 47,002 | 1,322,608 |
| Former Chief Financial Officer | ||||||||
| Mark Iwicki | 111,866 | 0 | 166,413 | 627,467 | 0 | 0 | 896 | 906,642 |
| Former Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Todd Bazemore | $3,476,972 | $949,550 | $2,943,656 | ↑ +2,527,422 |
| Kim Brazzell | 1,358,174 | 920,687 | 2,923,073 | ↑ +437,487 |
| Mary Reumuth | 1,322,608 | 778,269 | — | ↑ +544,339 |
| Mark Iwicki | 906,642 | 1,491,187 | 8,342,714 | ↓ −584,545 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation program is designed to motivate employees to achieve annual goals based on strategic, financial, and operating performance objectives, while equity grants are intended to provide a strong link to long-term performance, create an ownership culture, and align the interests of executives and stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Mary Reumuth | RSU | 512 | — | $285 |
| Todd Bazemore | RSU | 794 | — | 441 |
| Mark Iwicki | RSU | 2,450 | — | 1,362 |
| Mark Iwicki | RSU | 2,584 | — | 1,437 |
| Mary Reumuth | RSU | 3,067 | — | 1,705 |
| Mary Reumuth | RSU | 3,176 | — | 1,766 |
| Todd Bazemore | RSU | 4,268 | — | 2,373 |
| Todd Bazemore | RSU | 4,334 | — | 2,410 |
| Mark Iwicki | Option | 5,450 | 4.3 | — |
| Todd Bazemore | Option | 7,533 | 7.05 | — |
| Mark Iwicki | RSU | 9,534 | — | 5,301 |
| Todd Bazemore | RSU | 10,100 | — | 5,616 |
| Mary Reumuth | RSU | 10,100 | — | 5,616 |
| Mary Reumuth | Option | 10,677 | 7 | — |
| Mary Reumuth | RSU | 12,051 | — | 6,700 |
| Mark Iwicki | RSU | 13,903 | — | 7,730 |
| Todd Bazemore | RSU | 14,040 | — | 15,260 |
| Todd Bazemore | RSU | 16,236 | — | 9,027 |
| Mary Reumuth | Option | 18,072 | 14.56 | — |
| Mark Iwicki | RSU | 22,100 | — | 12,288 |
| Todd Bazemore | Option | 24,349 | 14.56 | — |
| Mark Iwicki | Option | 33,594 | 7 | — |
| Todd Bazemore | Option | 34,842 | 7.53 | — |
| Mary Reumuth | Option | 34,842 | 7.53 | — |
| Mark Iwicki | RSU | 52,969 | — | 29,451 |
| Mark Iwicki | Option | 76,698 | 7.53 | — |
| Mark Iwicki | Option | 79,437 | 14.56 | — |
| Todd Bazemore | Option | 165,000 | 11.22 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Andrew I. KovenIndependent · Departed during FY | $96,298 | $13,115 | $24,628 | — | — | $134,041 |
| Howard B. RosenIndependent · Departed during FY | 75,000 | 10,535 | 19,595 | — | — | 105,130 |
| Mark IwickiEmployee director · Departed during FY | 68,139 | 10,535 | 19,595 | — | — | 98,269 |
| C. Daniel MyersIndependent · Departed during FY | 67,500 | 10,535 | 19,595 | — | — | 97,630 |
| Marjan FaridIndependent · Departed during FY | 67,500 | 10,535 | 19,595 | — | — | 97,630 |
| Gregory D. PerryIndependent · Compensation · Departed during FY | 44,837 | 10,535 | 19,595 | — | — | 74,967 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $419,274 |
| Equity awards (grant-date value) | $65,790 |
| All other compensation | $0 |
| Total cost of the board | $485,064 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names KALA BIO as a peer
Companies that benchmark against KALA
2 companies name KALA as a compensation peer
- Evofem Biosciences, Inc.EVFMFY2024
- Passage BIO, Inc.PASGFY2025
Each company listed discloses KALA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named KALA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | KALA BIO, Inc. | 2025 | Mark Iwicki | $111,866 | $166,413 | $627,467 | $0 | $906,642 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-11 | 764,305 | 225,459 | 24,240 | 77.22% | Passed |
| 2023 | 2023-05-11 | 498,054 | 57,912 | 15,185 | 89.58% | Passed |
| 2022 | 2022-10-19 | — | — | — | — | — |
| 2021 | 2021-06-17 | — | — | — | — | — |
| 2019 | 2019-06-05 | — | — | — | — | — |
| 2018 | 2018-06-12 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-06-11 | 77.22%a |
| 2023 | 2023-05-11 | 89.58%b |
| 2022 | 2022-10-19 | —c |
a. Approved under the standard stated in the filing — “Accordingly, abstentions and broker non-votes will have no effect on the voting on Proposal 2.”.
b. Approved under the standard stated in the filing — “Accordingly, abstentions and broker non-votes will have no effect on the voting on Proposal 2.”.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (16 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Todd Bazemore. DEF 14A, filed 2026-09-24. Section “Executive Compensation”. As printed: 3,476,972. View filing ↗
- Section 01, Kim Brazzell. DEF 14A, filed 2026-09-24. Section “Executive Compensation”. As printed: 1,358,174. View filing ↗
- Section 01, Mary Reumuth. DEF 14A, filed 2026-09-24. Section “Executive Compensation”. As printed: 1,322,608. View filing ↗
- Section 01, Mark Iwicki. DEF 14A, filed 2026-09-24. Section “Executive Compensation”. As printed: 906,642. View filing ↗
- Section 08, Andrew I. Koven. DEF 14A, filed 2026-09-24. Section “Director Compensation”. As printed: 134,041. View filing ↗
- Section 08, Howard B. Rosen. DEF 14A, filed 2026-09-24. Section “Director Compensation”. As printed: 105,130. View filing ↗
- Section 08, Mark Iwicki. DEF 14A, filed 2026-09-24. Section “Director Compensation”. As printed: 98,269. View filing ↗
- Section 08, C. Daniel Myers. DEF 14A, filed 2026-09-24. Section “Director Compensation”. As printed: 97,630. View filing ↗
- Section 08, Marjan Farid. DEF 14A, filed 2026-09-24. Section “Director Compensation”. As printed: 97,630. View filing ↗
- Section 08, Gregory D. Perry. DEF 14A, filed 2026-09-24. Section “Director Compensation”. As printed: 74,967. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-12. Item 5.07 · say-on-pay result. As reported: 77.22% (votes for as printed: 764,305). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-23. Item 5.07 · say-on-pay result. As reported: 89.58% (votes for as printed: 498,054). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-10-20. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 419,274 + equity 65,790 + all other 0 = 485,064, summed across the director compensation table rows.
- KALA BIO, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-09-24. CEO total compensation as printed in KALA BIO, Inc.'s own proxy. As printed: 906,642. View filing ↗